GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (HKSE:02552) » Definitions » EV-to-FCF

Hua Medicine (HKSE:02552) EV-to-FCF : -2.25 (As of Apr. 21, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hua Medicine's Enterprise Value is HK$1,011.6 Mil. Hua Medicine's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-449.5 Mil. Therefore, Hua Medicine's EV-to-FCF for today is -2.25.

The historical rank and industry rank for Hua Medicine's EV-to-FCF or its related term are showing as below:

HKSE:02552' s EV-to-FCF Range Over the Past 10 Years
Min: -15.08   Med: -2.22   Max: 0.93
Current: -2.25

During the past 9 years, the highest EV-to-FCF of Hua Medicine was 0.93. The lowest was -15.08. And the median was -2.22.

HKSE:02552's EV-to-FCF is ranked worse than
100% of 546 companies
in the Drug Manufacturers industry
Industry Median: 23.31 vs HKSE:02552: -2.25

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-21), Hua Medicine's stock price is HK$1.93. Hua Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.268. Therefore, Hua Medicine's PE Ratio (TTM) for today is At Loss.


Hua Medicine EV-to-FCF Historical Data

The historical data trend for Hua Medicine's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hua Medicine EV-to-FCF Chart

Hua Medicine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -79.58 -7.00 -11.09 0.54 -1.16

Hua Medicine Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.09 - 0.54 - -1.16

Competitive Comparison of Hua Medicine's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hua Medicine's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Hua Medicine's EV-to-FCF falls into.


;
;

Hua Medicine EV-to-FCF Calculation

Hua Medicine's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1011.598/-449.52
=-2.25

Hua Medicine's current Enterprise Value is HK$1,011.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hua Medicine's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-449.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hua Medicine  (HKSE:02552) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Hua Medicine's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.93/-0.268
=At Loss

Hua Medicine's share price for today is HK$1.93.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hua Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.268.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Hua Medicine EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Hua Medicine's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Hua Medicine Business Description

Traded in Other Exchanges
N/A
Address
Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC.
Executives
Chen Li 2101 Beneficial owner
Hlyy Limited 2306 Nominee for another person
Tct (bvi) Limited 2501 Other
The Core Trust Company Limited 2301 Trustee
Hong Jane Xingfang 2202 Interest of your spouse
Wuxi Pharmatech Investments (cayman) Inc. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Investment Holdings (cayman) Inc. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Fund I General Partner L.p. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Healthcare Fund I L.p. 2101 Beneficial owner
Wuxi Apptec Co., Ltd. 2201 Interest of corporation controlled by you
Wuxi Apptec International Holdings Limited 2201 Interest of corporation controlled by you
Nelsen Robert Taylor 2101 Beneficial owner
Venrock Management V, Llc 2102 Investment manager
Harvest Yuanxiang (cayman) Limited 2101 Beneficial owner
Arch Venture Fund Vii, L.p. 2101 Beneficial owner

Hua Medicine Headlines

No Headlines